drugset / Trial / NCT00198354

Stage I/II NSCLC Perioperative Chemotherapy

NCT00198354 ↗

Phase 3 Completed 530 enrolled French Cooperative Thoracic Intergroup
RandomizedParallel-groupOpen-labelTreatment

Summary

The addition of chemotherapy to lung cancer surgery is now considered as the standard of care. Solid data support postoperative chemotherapy but only few results are available in the preoperative setting. To define which timing of perioperative chemotherapy offers the best survival improvement, the IFCT 0002 study is conducted in France.

Timeline

Start
2001-05
Primary completion
2009-12
Completion
2010-12

Outcome

Missed primary endpoint

paper Three-year OS did not differ between the two groups (67.4% and 67.7%, respectively; hazard ratio (HR)=1.01 [0.79-1.30], p=0.92) PMID 23735703 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 6 unknown —
Subject Cisplatin Other / unclassified 80 mg/m2 —
Subject Gemcitabine Small molecule 1250 mg/m2 —
Subject Paclitaxel Small molecule 200 mg/m2 —